The ๐๐ซ๐๐ณ๐จ๐ฉ๐ซ๐๐ฏ๐ข๐ซ ๐๐๐ซ๐ค๐๐ญ has evolved since it was first approved for the treatment of chronic hepatitis C virus (HCV) infection in 2016. Initially, grazoprevir was launched as a combination therapy with elbasvir under the brand name Zepatier, and it was positioned as an alternative treatment option for HCV genotype 1 and 4 infections.
However, since the introduction of Zepatier, there have been several newer and more effective treatments for HCV, such as the combination of sofosbuvir and Velpatasvir. These newer treatments have gradually replaced Zepatier and grazoprevir in the HCV treatment landscape, resulting in a decline in the market for grazoprevir.
As a result, the manufacturer of grazoprevir, Merck & Co., Inc., announced in 2018 that it would be discontinuing the production and distribution of Zepatier by the end of 2020 in most markets. However, it should be noted that Zepatier is still available in some countries, and it may still be used in certain circumstances, depending on the patient’s specific HCV genotype and treatment history.
๐๐๐ญ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ@ย https://www.alliedmarketresearch.com/request-toc-and-sample/12844
๐๐๐๐๐-๐๐ ๐๐ฆ๐ฉ๐๐๐ญ ๐๐ง๐๐ฅ๐ฒ๐ฌ๐ข๐ฌ:
COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19.
Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the grazoprevir market.
Procure Complete Report (220 Pages PDF with Insights, Charts, Tables, and Figures) @ย https://www.alliedmarketresearch.com/checkout-final/33b9a2a7105e18c839f79455779374af
The World Health Organization (WHO) on January 30, 2020, declared COVID-19 outbreak a public health emergency of international concern. Grazopervir API and tablet manufacturing and distributing companies have been affected by COVID-19 to a limited extent, owing to shut down in various COVID-19 affected countries and rise in number of healthcare workers falling ill in the wake of the COVID-19 pandemic, leading to supply shortage.
๐๐ข๐ฌ๐ ๐ข๐ง ๐ฉ๐ซ๐๐ฏ๐๐ฅ๐๐ง๐๐ ๐จ๐ ๐๐๐ฉ๐๐ญ๐ข๐ญ๐ข๐ฌ ๐ ๐๐๐ฌ๐๐ฌ ๐ข๐ฌ ๐ฅ๐ข๐ค๐๐ฅ๐ฒ ๐ญ๐ก๐ ๐ค๐๐ฒ ๐๐ซ๐ข๐ฏ๐ข๐ง๐ ๐๐๐๐ญ๐จ๐ซ ๐จ๐ ๐ ๐ซ๐๐ณ๐จ๐ฉ๐ซ๐๐ฏ๐ข๐ซ ๐ฆ๐๐ซ๐ค๐๐ญ ๐ข๐ง ๐ฎ๐ฉ๐๐จ๐ฆ๐ข๐ง๐ ๐ฒ๐๐๐ซ๐ฌ. However, the restraints to the market are self-imitating nature of the disease in a sizable number of patients, challenge of herbal treatment offered at negligible prices especially in developing regions, price war between companies, rising urbanization, and better sanitation.
The global Grazoprevir Drug Market is expected to witness significant growth during the forecast period. Key players such as Merck & Co. has taken initiative for the treatment of hepatitis C infection in Africa by formulation of grazoprevir. Hepatitis C is a viral infection that causes severe damage such as inflammation of the liver and can spread through contaminated blood. The advanced stages of hepatitis C can also lead to liver damage, thereby creating severe health risks. The severity of hepatitis C has created a huge emphasis on the R&D of drugs associated with the treatment of this disease.
๐๐จ๐ฉ ๐๐ฆ๐ฉ๐๐๐ญ๐ข๐ง๐ ๐ ๐๐๐ญ๐จ๐ซ๐ฌ:
โข Rise in prevalence of Hepatitis C cases is likely the key driving factor of grazoprevir market in upcoming years.
โข However, the restraints to the market are self-imitating nature of the disease in a sizable number of patients, challenge of herbal treatment offered at negligible prices especially in developing regions, price war between companies, rising urbanization, and better sanitation.
โขSeveral new drugs have been launched in recent times, due to the high prevalence of hepatitis C across the world, which can restrain the grazoprevir market growth.
๐ ๐จ๐ซ ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ง๐ช๐ฎ๐ข๐ซ๐ฒ ๐๐ญ:ย https://www.alliedmarketresearch.com/purchase-enquiry/12844
๐๐๐ฒ ๐๐๐ง๐๐๐ข๐ญ๐ฌ ๐จ๐ ๐๐๐ฉ๐จ๐ซ๐ญ:
โข This report presents the detailed analytical depiction of the grazoprevir market along with current trends, opportunities, and future estimates for the market.
โข The report presents information related to the key drivers, restraints, and opportunities in the grazoprevir market.
โข The current market is analyzed from 2020 to 2028 to emphasize the grazoprevir market.
โข Porter’s five forces analysis illustrate the potency of buyers and suppliers in market.
โข The report provides a detailed analysis of the grazoprevir market based on market competition and how it will take shape in upcoming years.
Other Trending Reports:
Acupuncture Needles Marketย
https://www.alliedmarketresearch.com/acupuncture-needles-market
Cystic Fibrosis (CF) Therapeutics Marketย
https://www.alliedmarketresearch.com/cystic-fibrosis-therapeutics-market
Contact Us:
David Correa
Portland, OR, United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022,
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web:ย https://www.alliedmarketresearch.com
About Us:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.